Res Nova Biologics Recruits Abortion Pill Reversal Founder to Scientific Advisory Board
Oncology-Focused Therapeutic Solutions International Subsidiary Seeks to Enter Clinical Trials of "Repurposed" Abortion Pill for Breast Cancer
ELK CITY, Idaho, October 17, 2023--(BUSINESS WIRE)--The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.Therapeutic Solutions International, Inc. (TSOI), announced today its breast cancer focused immunotherapy subsidiary company, Res Nova Bio, has recruited internationally renowned medical doctor George Delgado to its Scientific Advisory Board.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231017959162/en/
George Delgado, M.D.
Dr. Delgado is an expert in the biology of pregnancy and the abortion pill, being the founder of "Abortion Pill Reversal" and having been the first to publish in the peer-reviewed literature successful reversal of mifepristone administration using progesterone treatment1.
Res Nova is developing FloraStilbene™, a proprietary formulation of RU-486 and pterostilbene which has been shown to overcome tumor associated immune suppression2 and increases responsiveness to chemotherapy and immunotherapy3. The Company has signed a collaborative agreement with Cure Stat Rx4, a premiere compounding pharmacy and plans to eventually commercialize through the 505b2 pathway.
"The similarities between pregnancy and oncology, including angiogenesis, immune modulation, and rapid growth are striking," said Dr. George Delgado. "In my opinion the concept of leveraging the effects of the abortion pill in life-saving as opposed to a life-taking scenario is extremely exciting. I am proud to join such a specialized team of therapeutic developers in advancing this novel approach to tumor immunotherapy."
"Dr. Delgado is a medical visionary whose passion is protecting and preserving life," said Timothy Dixon, President, and CEO of Therapeutic Solutions International. "We are honored to have Dr. Delgado join Famela and her team in addressing the problem of tumor associated immune suppression, which is a major hurdle to widespread implementation of immune therapy of cancer."
"Having known the work of Dr. Delgado for many years and his great success in defending both the mother and the baby, it is exciting to have the opportunity to utilize his scientific and medical expertise in this unique intersection of reproductive medicine, immunology, and oncology," said Famela Ramos, President, and CEO of Res Nova Bio.
Dr. Delgado received his undergraduate degree at St. Mary’s College of California where he graduated summa cum laude and received the biology department’s top honor — the Carlos Freitas Award. He attended medical school at UC Davis and completed his residency training at Santa Monica Hospital/UCLA. He has given numerous presentations to various groups on medical and bioethical topics.
About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com.
1 Delgado and Davenport, Progesterone Use to Reverse the Effects of Mifepristone, Annals of Pharmacotherapy 2012; 46
2 Novel Mechanism of Action of FloraStilbene Suggests Potential for Enhancing Efficacy of Checkpoint Inhibitor, CAR-T Therapies (pharmacytimes.com)
3 FloraStilbene™ Demonstrates Synergy with Conventional Chemotherapy and Immunotherapy in Reducing Triple Negative Breast Cancer | Business Wire
4 Therapeutic Solutions International Spin-Off Res Nova Bio Partners with Cure Stat Rx to Manufacture First in Class Breast Cancer Immunotherapy Product FloraStilbene™ | Business Wire
View source version on businesswire.com: https://www.businesswire.com/news/home/20231017959162/en/
Contacts
Timothy G. Dixon
ir@tsoimail.com
